The Predictive Value of PITX2 DNA Methylation for High-Risk Breast Cancer Therapy: Current Guidelines, Medical Needs, and Challenges
Table 2
Current therapeutic regimens for breast cancers contain.
(i) For patients with luminal A/B tumors (ER/PR+, HER2ā): endocrine therapy or chemotherapy followed by endocrine therapy. (ii) For patients with HER2+ tumors: chemotherapy plus anti-HER2 therapy (e.g., with trastuzumab/pertuzumab) and, if appropriate, endocrine therapy. The combination with chemotherapy is currently recommended since by this therapy a survival benefit for the patients has been reported [4]. (iii) For TNBC patients: chemotherapy (anthracycline plus taxane) (AGO guidelines 2016: http://www.ago-online.de/en/guidelines-mamma/march-2016).
